for cystic fibrosis
FDA approved expanded use of Alyftrek and Trikafta for cystic fibrosis treatment, increasing availability to ~95% of patients.
Cystic fibrosis is a genetic disorder that causes thick mucus to build up in the lungs and other organs, leading to frequent infections, breathing difficulties, and complications in digestion and growth. Alyftrek and Trikafta combine multiple drugs that work together to improve the function of a faulty protein responsible for mucus buildup. By restoring this protein’s activity, these treatments may help clear mucus, reduce infections, and improve breathing and overall health for people with cystic fibrosis.